e18520 Background: The role of serum CA125 in the prognosis of non-small cell lung cancer (NSCLC) remains controversial, especially in early stage patients. The aim of this study is to analyze the prognostic value of CA125 in operable NSCLC. Methods: We retrospectively analyzed 645 patients with non-small cell lung cancer (NSCLC) who underwent curative surgical resection for lung cancer at Zhejiang Cancer Hospital of China from 2006 to 2011. Micropartical enzyme immunoassay was used to measure preoperative serum CA125. Pearson’s chi test was used in univariate analyses and a multivariable proportional hazard Cox regression model was applied to assess the prognostic significance of the different covariates. Kaplan-Meier was used to analyze survival curve. Results: The positive rate of preoperative serum CA125 was 18.9% (126/667) in all patients, and elevated CA125 concentration was associated to poorly differentiated tumor and advanced clinical stage. Moreover, CA125 was closely related to patient outcomes. The Kaplan-Meier survival curves were shown patient with normal CA125 concentration had significantly longer DFS (median DFS, not reach vs 21 months, p=0.000) and OS (median OS, 61 vs 29 months, p=0.000) than those with positive CA125. Multivariate Cox analysis indicated patients with positive CA125 had an elevated risk of disease recurrence or death compared with those who had negative one. The adjusted hazard ratio (HR) was 1.74 for replase (95% confidence interval [CI], 1.25-2.41, p=0.001) and 1.79 for death (95% CI, 1.34-2.41, p=0.000) after adjusted by age, gender, grade, stage, histology and smoking status. Conclusions: CA125 seems to play an important role in disease progression and it may be an independent predictive marker for prognosis in patients with NSCLC. [Table: see text]
P72.10 Prognostic Significance of IgA+ B Cells in Non-Small Cell Lung Cancer
